Acta Diabetologica

, Volume 50, Issue 3, pp 417–422 | Cite as

Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women

  • Eiji OdaEmail author
  • Yoshifusa Aizawa
Original Article


Serum total bilirubin (TB) is a potent antioxidant and inversely associated with metabolic syndrome (MetS) in Asian populations. However, there has been no study which is aimed to investigate whether TB is a risk factor for MetS or not. We investigated cross-sectional and longitudinal associations between TB and MetS in 2,435 Japanese men and 1,436 Japanese women. The odds ratios [95 % confidence interval (CI)] of coexisting MetS for each 1 SD increase in log TB were 0.850 (0.754–0.958) (p = 0.008) in men and 0.809 (0.656–0.998) (p = 0.047) in women adjusted for sex, age, smoking, and other confounding covariates. Those for the third and fourth quartiles of TB compared with the lowest quartile were 0.720 (0.537–0.965) (p = 0.028) and 0.737 (0.530–1.052) (p = 0.095), respectively, in men and 0.822 (0.473–1.427) (p = 0.486) and 0.704 (0.362–1.369) (p = 0.301), respectively, in women. There was a tendency that TB and MetS changed inversely to each other. The similarly adjusted hazard ratios of developing MetS for each 1 SD increase in log TB and for the higher quartiles of TB compared with the lowest quartile were not significant either in men or in women. TB is inversely associated with MetS but not a risk factor for MetS in Japanese men and women.


Bilirubin Metabolic syndrome Oxidative stress Risk factor 



The authors thank all subjects who participated in the study and the paramedical staff at our center who assisted with the study. The authors received no financial support for this study and have no conflict of interest to disclose.

Conflict of interest


Supplementary material

592_2012_447_MOESM1_ESM.jpg (44 kb)
Supplementary material 1 (JPEG 44 kb)


  1. 1.
    Oda E (2012) Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49:89–95PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization (1999) Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. World Health Org, GenevaGoogle Scholar
  3. 3.
    Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
  4. 4.
    Alberti KGMM, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23:469–480PubMedCrossRefGoogle Scholar
  5. 5.
    Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: a statement for health care professionals: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752PubMedCrossRefGoogle Scholar
  6. 6.
    Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRefGoogle Scholar
  7. 7.
    Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304PubMedCrossRefGoogle Scholar
  8. 8.
    Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600–605PubMedCrossRefGoogle Scholar
  9. 9.
    Oda E (2008) The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 31:1283–1291PubMedCrossRefGoogle Scholar
  10. 10.
    Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259:87–91PubMedCrossRefGoogle Scholar
  11. 11.
    Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM, Wilson PWF, Grandy SM (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818–2825PubMedCrossRefGoogle Scholar
  13. 13.
    Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607PubMedCrossRefGoogle Scholar
  14. 14.
    Kim J, Montagnani M, Koh KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 113:1888–1904PubMedCrossRefGoogle Scholar
  15. 15.
    Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN (1987) Bilirubin is an antioxidant of possible physiological importance. Science 235:1043–1046PubMedCrossRefGoogle Scholar
  16. 16.
    Wu TW, Fung KP, Yang CC (1994) Unconjugated bilirubin inhibits the oxidation of human low-density lipoprotein better than Trolox. Life Sci 54:477–481Google Scholar
  17. 17.
    Sedlak TW, Saleh M, Higginson DS, Paul BD, Juluri KR, Snyder SH (2009) Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. Proc Natl Acad Sci USA 106:5171–5176PubMedCrossRefGoogle Scholar
  18. 18.
    Frei B, Stocker R, Ames BN (1988) Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85:9748–9752PubMedCrossRefGoogle Scholar
  19. 19.
    Vítek L, Schwertner HA (2007) The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 43:1–57PubMedCrossRefGoogle Scholar
  20. 20.
    Lin LY, Kuo HK, Hwang JJ et al (2009) Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 203:563–568PubMedCrossRefGoogle Scholar
  21. 21.
    Wu Y, Li M, Xu M et al (2011) Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese. J Diabetes 3:217–224PubMedCrossRefGoogle Scholar
  22. 22.
    Choi SH, Yun KE, Choi HJ (2011) Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc [Epub ahead of print]. doi: 10.1016/j.numecd.2011.03.001
  23. 23.
    Kwon KM, Kam JH, Kim MY et al (2011) Inverse association between total bilirubin and metabolic syndrome in rural Korean women. J Womens Health (Larchmt) 20:963–969CrossRefGoogle Scholar
  24. 24.
    Maruhashi T, Soga J, Fujimura N et al (2012) Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in gilbert syndrome. Circulation 126:598–603PubMedCrossRefGoogle Scholar
  25. 25.
    Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR (1996) Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16:250–255PubMedCrossRefGoogle Scholar
  26. 26.
    Troughton JA, Woodside JV, Young IS et al (2007) Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 14:79–84PubMedCrossRefGoogle Scholar
  27. 27.
    Oda E, Kawai R (2012) A possible cross-sectional association of serum total bilirubin with coronary heart disease and stroke in a Japanese health screening population. Heart Vessel 27:29–36CrossRefGoogle Scholar
  28. 28.
    Oda E, Kawai R (2011) Bilirubin is negatively associated with hemoglobin a(1c) independently of other cardiovascular risk factors in apparently healthy Japanese men and women. Circ J 75:190–195PubMedCrossRefGoogle Scholar
  29. 29.
    Fukui M, Tanaka M, Shiraishi E et al (2008) Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes. Kidney Int 74:1197–1201PubMedCrossRefGoogle Scholar
  30. 30.
    Kuwano T, Miura S, Shirai K et al (2011) Serum levels of bilirubin as an independent predictor of coronary in-stent restenosis: a new look at an old molecule. J Atheroscler Thromb 18:574–583PubMedCrossRefGoogle Scholar
  31. 31.
    Huang SS, Huang PH, Leu HB, Wu TC, Lin SJ, Chen JW (2010) Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome X. Heart 96:1227–1232PubMedCrossRefGoogle Scholar
  32. 32.
    Oda E, Aoyagi R, Aizawa Y (2012) Hypobilirubinemia might be a possible risk factor of end-stage kidney disease independently of estimated glomerular filtration rate. Kidney Blood Press Res 36:47–54PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  1. 1.Medical Check-up CenterTachikawa Medical CenterNagaokaJapan
  2. 2.Department of Research and DevelopmentTachikawa Medical CenterNagaokaJapan

Personalised recommendations